home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Researcher Issues Caution On Live Virus Vaccines

 
  June, 22 2004 8:12
your information resource in human molecular genetics
 
     
VALHALLA, N.Y., June 18, 2004 - A New York Medical College microbiologist warns that live virus vaccines to prevent infectious diseases like West Nile virus and yellow fever could have dire consequences. Should one of the vaccine flaviviruses recombine with a wild-type virus, a new microbe with potentially undesirable properties could result, according to Stephen J. Seligman, M.D., research professor of microbiology and immunology.

His paper, "Live flavivirus vaccines: reasons for caution" appears as a rapid review article in the June 19, 2004, issue of the journal Lancet. Co-author is Ernest A. Gould, Ph.D., of CEH-Oxford in the UK.

Flaviviruses, which can recombine within species and may recombine between species, also include dengue, Japanese encephalitis and tick-borne encephalitis. They cause substantial sickness and death each year. Although live-virus vaccines offer great promise in terms of cost and efficacy, their use should be approved by an international authority due to safety concerns, the authors write.

The article lists five main lessons learned from other live virus vaccines: reversion of vaccine strains to increased virulence; development of disease in individuals with compromised immune systems; birth defects, particularly if the vaccine is given in the first trimester; spread of vaccine strains to unvaccinated persons; and the discovery of new, previously undetermined complications.

(C) 2004, New York Medical College

Seligman SJ, Gould EA. Live flavivirus vaccines: reasons for caution.
Lancet. 2004 Jun 19;363(9426):2073-2075.


Message posted by: Frank S. Zollmann

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.